Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ensysce Biosciences, Inc. - Common Stock (NQ:ENSC)

0.3953 +0.0031 (+0.79%)
Streaming Delayed Price Updated: 11:12 AM EST, Feb 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ensysce Biosciences, Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
Good morning! We're starting off Thursday with an overview of the biggest pre-market stock movers that traders need to watch! 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
  
Via Benzinga
News headline image
Ensysce Biosciences Announces Completion of $8 Million Convertible Note Financing
Via ACCESSWIRE
News headline image
Recap of Wednesday's Biotech Catalysts - End of The Day Summary ↗
 
Via Benzinga
News headline image
Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday ↗
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  On Friday, 72 companies set new 52-week lows. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers 
Via Benzinga
News headline image
Ensysce Biosciences Announces Positive Bioequivalence (BE) Study Data of Novel "TAAP" Opioid PF614 and Provides Timing of Corporate Update Call
Via ACCESSWIRE
News headline image
Ensysce Biosciences Announces Positive Bioequivalence (BE) Study Data of Novel "TAAP" Opioid PF614 and Provides Timing of Corporate Update Call
~ BE Study of PF614 Represents Critical Progress Toward FDA Approval ~~ Supports the 505(b)(2) Regulatory Path for Clinical Development of PF614 ~SAN DIEGO, CA / ACCESSWIRE / July 27, 2022 / Ensysce... 
From Ensysce Biosciences, Inc.
Via AccessWire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Gainers 
Via Benzinga
News headline image
Ensysce Biosciences Announces Initial Patients Dosed of First Human Abuse Potential Study
~ Trial Designed to Test and Confirm Nasal Opioid Manipulation ~ 
From Ensysce Biosciences, Inc.
Via AccessWire
News headline image
Accolade Shares Jump Around 29%, Here's 75 Biggest Movers From Friday ↗
Gainers Omeros Corporation (NASDAQ: OMER) jumped 68.7% to close at $4.64. Clovis Oncology, Inc. (NASDAQ: CLVS) gained 58.3% to settle at $2.85 on Friday. 
Via Benzinga
News headline image
Why Is Akebia Therapeutics Surging By 28%? 48 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) rose 56.1% to $ 0.7029 after dropping 10% on Thursday. 
Via Benzinga
News headline image
Why Is Akebia Therapeutics (AKBA) Stock Up 14% Today? ↗
Akebia Therapeutics (AKBA) stock is taking off on Friday after the kidney treatment company revealed the return of rights for vadadustat. 
Via InvestorPlace
News headline image
Why Is Ensyce Biosciences (ENSC) Stock Down 27% Today? ↗
Ensyce Biosciences (ENSC) stock is taking a beating on Friday after the clinical-stage biotech company announced $8 million in financing. 
Via InvestorPlace
News headline image
Ensysce Biosciences Secures $8 Million Convertible Note Financing
~ Additional Funding from Investor Cohort Validates Company's Mission ~ 
From Ensysce Biosciences, Inc.
Via AccessWire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Akebia Therapeutics And 20 Stocks Moving Premarket ↗
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) rose 83.2% to $0.8250 in pre-market trading after dropping 10% on Thursday. 
Via Benzinga
News headline image
Akerna Shares Dip 53%, Here's 78 Biggest Movers From Yesterday ↗
Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase... 
Via Benzinga
News headline image
Ensysce Biosciences Receives Notice of Award for 4th Year of Funding for Its Multi-Pill Abuse Resistance (MPAR(TM)) Platform
SAN DIEGO, CA / ACCESSWIRE / June 27, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC) (OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to... 
From Ensysce Biosciences, Inc.
Via AccessWire
News headline image
Ensysce Biosciences Reminds Shareholders to Vote At Upcoming 2022 Virtual Annual Shareholder Meeting
- Shareholder Meeting to be Held on Thursday, June 23rd at 9:00 AM PT 
From Ensysce Biosciences, Inc.
Via AccessWire
Topics Death Intellectual Property
News headline image
The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Ensysce Biosciences Announces Initiation of First Human Abuse Potential Study
~ Nasal Opioid Abuse Being Explored for PF614 ~ 
From Ensysce Biosciences, Inc.
Via AccessWire
News headline image
Ensysce Biosciences Provides Business Update and Reports First Quarter 2022 Financial Results
Corporate Update Call to be Held Tuesday, May 17, 2022 SAN DIEGO, CA / ACCESSWIRE / May 12, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage... 
From Ensysce Biosciences, Inc.
Via AccessWire
News headline image
Ensysce Biosciences Releases 2021 Annual Shareholder Letter
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From Ensysce Biosciences, Inc.
Via AccessWire
Topics Death Intellectual Property Regulatory Compliance
Global Antibiotic Resistance Market to Hit US$16.5 Billion By 2030
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 21, 2022 – Resistance to antibiotics is a growing concern. About 750,000 people die each year worldwide from... 
Via FinancialNewsMedia
News headline image
Dr. Lynn Kirkpatrick, Invited Speaker at SMi 22nd Annual Pain Therapeutics Conference in London UK
SAN DIEGO, CA / ACCESSWIRE / April 20, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to... 
From Ensysce Biosciences, Inc.
Via AccessWire
News headline image
Ensysce Biosciences Announces Appointment of Dr. Nily Osman as Chief Medical Officer
SAN DIEGO, CA / ACCESSWIRE / April 18, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to... 
From Ensysce Biosciences, Inc.
Via AccessWire
News headline image
51 Biggest Movers From Yesterday ↗
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares surged 148.2% to close at $5.61 on Tuesday after the company announced that two of its designed mRNA molecules are... 
Via Benzinga
News headline image
Earnings Scheduled For March 31, 2022 ↗
Companies Reporting Before The Bell • Trevena (NASDAQ:TRVN) is likely to report earnings for its fourth quarter. 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.